Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Barr Laboratory BRL -- Ignore unavailable to you. Want to Upgrade?

To: E. Graphs who wrote (176)	7/19/1999 7:10:00 PM
From: E. Graphs	Respond to of 207

I don't know anyone who suffers from this disease, but I imagine these false claims must be particularly cruel. Who can trust any drug company that leads people down the wrong path as they try to deal with a health problem as serious as this one? If I am understanding it correctly, this effort on the part of Lilly was unbelievably low. Glad they got nailed. biz.yahoo.com >>...U.S. District Court Judge John G. Koeltl's preliminary injunction prohibits Lilly from ''stating in its advertising or promotional activities that EVISTA has been proven, shown or demonstrated to reduce the risk of breast cancer, or that EVISTA has been proven comparable or superior to Tamoxifen in the reduction of the risk of breast cancer.'' Judge Koeltl also ordered Lilly to implement a training program for its sales representatives to ensure the representatives adhere to the Court's preliminary injunction. ''The judge's decision is a victory for breast cancer patients, who Lilly has misled in their attempt to promote sales of EVISTA,'' said Bruce L. Downey, Barr's Chairman, President and CEO. ''In making his ruling, Judge Koeltl noted that 'when an allegedly false claim pertains to a prescription drug, the public interest in receiving truthful information is particularly acute.' Lilly's claims have now been determined by the Court to be false. Hopefully, this will end any confusion created by Lilly among patients and physicians who are trying to determine the best course of therapy to treat this terrible disease.'' In February, Zeneca filed a federal suit charging Lilly with violating the Lanham Act, the New York General Business Law and common law of the State of New York. In March, Barr joined the case as a plaintiff because ''Barr's damages from Lilly's conduct are equal to, if not greater than Zeneca's.'' Currently, four out of every five breast cancer patients in the United States use the Tamoxifen Citrate distributed by Barr. Tamoxifen is the only drug approved by the U.S. Food and Drug Administration (FDA) for the reduction in incidence of breast cancer in women at high risk for developing this disease...<<